Form 4: Medpace CEO Sells Shares Under 10b5-1 Plan

Medpace Holdings CEO August J. Troendle sold over 31,000 shares of common stock in mid-November 2025 through a pre-arranged 10b5-1 plan.

Summary

• August J. Troendle, CEO, Director, and 10% Owner of Medpace Holdings, Inc. (MEDP), reported sales of common stock.
• On November 18, 2025, Mr. Troendle sold 7,191 shares of common stock at a weighted average price of $590.84 per share.
• On November 19, 2025, an additional 23,862 shares of common stock were sold at a weighted average price of $592.07 per share.
• The total number of shares sold across both transactions was 31,053.
• Following these transactions, Mr. Troendle directly beneficially owns 862,315 shares of common stock.
• Mr. Troendle also indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, where he is the sole manager and controlling unit holder.
• All reported transactions were executed pursuant to a limit order placed by Mr. Troendle during an open window period, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 4

Explanation: The CEO sold a significant number of shares, which can be perceived negatively by investors. However, the sales were conducted under a pre-arranged Rule 10b5-1 plan, which suggests the transactions were not based on new, undisclosed material information, thus mitigating some of the negative sentiment.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 plan, which indicates the transactions were scheduled in advance and not based on new, undisclosed material information, providing transparency to investors.

Negatives

• A significant sale of 31,053 shares by a high-ranking insider (CEO, Director, and 10% Owner) could be interpreted by some investors as a potential lack of confidence, despite being pre-planned.

Risks

• Insider selling, even when pre-planned, can sometimes lead to negative market sentiment or speculation regarding the company's future prospects.

Related Party Transactions

• August J. Troendle indirectly beneficially owns 4,733,019 shares of Medpace Holdings, Inc. through Medpace Investors, LLC, where he serves as the sole manager and controlling unit holder. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may interpret the insider selling as a signal, potentially affecting investor confidence or leading to increased scrutiny of the company's valuation, even with the 10b5-1 plan in place.

Key Dates

Keywords

Medpace Holdings, MEDP, August J. Troendle, Insider Trading, Stock Sale, Form 4, 10b5-1 Plan, CEO, Beneficial Ownership